Drug Details

General Information of the Drug (ID: DR8652)
Name
SG611-VSTM1
Molecular Type
Gene therapy
Disease Acute lymphoblastic leukemia [ICD-11: 2B33] Investigative [1]
Combinatorial Therapeutic Effect(s) Validated Clinically or Experimentally
    α. A List of Natural Product(s) Able to Enhance the Efficacy of This Drug
          Daunorubicin      Streptomyces peucetius     Click to Show/Hide the Molecular Data of This NP
                 Achieving Therapeutic Synergy     Click to Show/Hide
                    Representative Experiment Reporting the Effect of This Combination [1]
                    Detail(s)  Combination Info  click to show the detail info of this combination
                    In-vitro Model K-562 CVCL_0004 Chronic myelogenous leukemia Homo sapiens
                    In-vivo Model For a xenograft model, 1*109 human K562 cells were injected into the inguinal mammary fat pad of Balb/c congenic athymic nude mice.
                    Experimental
                    Result(s)		 An important role for VSTM1 in the pathogenesis of leukemia, and SG611-VSTM1 may be a promising agent for enhancing chemosensitivity in leukemia therapy.
Target and Pathway
Target(s) Bacterial Enterobacter Beta-lactamase (Bact ampC)  Molecule Info  [2]
References
Reference 1 Synergistic antitumor activity of triple-regulated oncolytic adenovirus with VSTM1 and daunorubicin in leukemic cells. Apoptosis. 2016 Oct;21(10):1179-90.
Reference 2 In vitro activity of avibactam (NXL104) in combination with Beta-lactams against Gram-negative bacteria, including OXA-48 Beta-lactamase-producing Klebsiella pneumoniae. Int J Antimicrob Agents. 2012 Jan;39(1):86-9.
 Download Picture         KEGG Link